OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Connie Batlevi, MD, PhD, explains the treatment options for relapsed/refractory follicular lymphoma and discusses a recent drug approval.
September 7th 2021
Connie Batlevi, MD, PhD, discusses the rate of patient relapse and current treatment options and considerations for relapsed/refractory follicular lymphoma.
An expert in follicular lymphoma highlights the therapies available for third-line relapsed/refractory treatment options.
September 14th 2021
Connie Batlevi, MD, PhD, explains the recent approval of tazemetostat, as well as the use of molecular testing in follicular lymphoma.
Connie Batlevi, MD, PhD, discusses how the sequencing of follicular lymphoma therapies has changed in the past year and looks to the future with the upcoming American Society of Hematology (ASH) annual meeting.